CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: Previous reports in cell lines have shown that imatinib can rescue BCR-ABL-dependent inhibition of FOXO TFs 21,22; however, this is the first report that elucidates the role of FOXO TFs in CML versus normal human hemopoietic cells, including CD34+ cells.